These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 35816218)

  • 21. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.
    Hong SH; Chu H; Kim KR; Ko MH; Kwon SY; Moon IJ; Chung WH; Cho YS; Kim CH; Suh MW; Choi EW; Sohn YB; Park SW; Kim SH; Cho SY; Ko AR; Jin DK
    Am J Med Genet A; 2012 Sep; 158A(9):2131-8. PubMed ID: 22847837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation.
    Jacques CE; Donida B; Mescka CP; Rodrigues DG; Marchetti DP; Bitencourt FH; Burin MG; de Souza CF; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2016 Sep; 1862(9):1608-16. PubMed ID: 27251652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation.
    Lee JH; Choe YH; Kim SJ; Paik KH; Jin DK
    Yonsei Med J; 2011 Mar; 52(2):263-7. PubMed ID: 21319344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in MPS I and MPS II Disease Manifestations.
    Hampe CS; Yund BD; Orchard PJ; Lund TC; Wesley J; McIvor RS
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.
    Tomanin R; Zanetti A; D'Avanzo F; Rampazzo A; Gasparotto N; Parini R; Pascarella A; Concolino D; Procopio E; Fiumara A; Borgo A; Frigo AC; Scarpa M
    Orphanet J Rare Dis; 2014 Sep; 9():129. PubMed ID: 25231261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan.
    Chuang CK; Lin HY; Wang TJ; Huang YH; Chan MJ; Liao HC; Lo YT; Wang LY; Tu RY; Fang YY; Chen TL; Ho HC; Chiang CC; Lin SP
    Orphanet J Rare Dis; 2018 May; 13(1):84. PubMed ID: 29801497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
    Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
    Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients.
    Coppa GV; Buzzega D; Zampini L; Maccari F; Galeazzi T; Pederzoli F; Gabrielli O; Volpi N
    Glycobiology; 2010 Oct; 20(10):1259-73. PubMed ID: 20538645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
    de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
    Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond.
    Zanetti A; Tomanin R
    BioDrugs; 2024 Sep; 38(5):639-655. PubMed ID: 39177874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycosaminoglycan fragments as a measure of disease burden in the mucopolysaccharidosis type I mouse.
    Saville JT; McDermott BK; Fuller M
    Mol Genet Metab; 2018 Feb; 123(2):112-117. PubMed ID: 29273385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
    Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
    Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
    Entchev E; Jantzen I; Masson P; Bocart S; Bournique B; Luccarini JM; Bouchot A; Lacombe O; Junien JL; Broqua P; Tallandier M
    PLoS One; 2020; 15(5):e0233032. PubMed ID: 32413051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment.
    Mohamed S; He QQ; Singh AA; Ferro V
    Adv Carbohydr Chem Biochem; 2020; 77():71-117. PubMed ID: 33004112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I.
    Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; de Carvalho TG; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Sakura N; Barrera L; Kida K; Kubota M; Orii T
    J Inherit Metab Dis; 2010 Apr; 33(2):141-50. PubMed ID: 20162367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry.
    Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Barrera LA; Kida K; Kubota M; Orii T
    Mol Genet Metab; 2010 Feb; 99(2):124-31. PubMed ID: 19932038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses.
    Lin HY; Lee CL; Lo YT; Wang TJ; Huang SF; Chen TL; Wang YS; Niu DM; Chuang CK; Lin SP
    Mol Genet Genomic Med; 2018 Nov; 6(6):982-992. PubMed ID: 30296009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses.
    Auray-Blais C; Lavoie P; Tomatsu S; Valayannopoulos V; Mitchell JJ; Raiman J; Beaudoin M; Maranda B; Clarke JT
    Anal Chim Acta; 2016 Sep; 936():139-48. PubMed ID: 27566349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmatic kinetics of dermatan sulfate during enzyme replacement therapy with iduronate-2-sulfatase in a mucopolysaccharidosis II patient.
    Volpi N; Zampini L; Maccari F; Santoro L; Galeotti F; Galeazzi T; Gabrielli O; Coppa GV
    Glycoconj J; 2013 Oct; 30(7):727-32. PubMed ID: 23512580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.